SEC Form 4 · accession 0000899243-18-000458
INFINITY PHARMACEUTICALS, INC. · INFI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Adelene Q Perkins
Officer — Chief Executive Officer · Director
Period of report
Jan 2, 2018
Accepted (ET)
Jan 4, 2018 · 4:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001113148
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 2, 2018 | A | 69,924 | $0.00 | A | 612,252 | D | |
| Common Stock | holding | — | — | — | 12,391 | I | 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $2.23 | Jan 2, 2018 | A | 180,000 | A | — | Jan 2, 2028 | Common Stock | 180,000 | 180,000 | D |
Explanation of responses
- F1Represents the reporting person's 2017 contingent compensation award paid in shares of common stock in lieu of cash at the election of the Compensation Committee of the issuer's Board of Directors.
- F2Includes 7,308 shares of common stock acquired by Ms. Perkins on December 15, 2017 through participation in the issuer's Employee Stock Purchase Plan.
- F3The option vests over a period of two years in equal annual installments on the first and second anniversary of the date of grant.